| Name | ZLN005 |
| Description | ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α. |
| In vitro | ZLN005 (15 mg/kg, p.o.) exhibits anti-hyperglycemic and anti-hyperlipidemic effects, and enhances insulin sensitivity in db/db mice without effecting lean mice. |
| In vivo | In L6 myotubes, ZLN005 enhances glucose uptake and fatty acid oxidation by activating AMP-activated protein kinase (AMPK), and it elevates the expression of PGC-1α genes and downstream genes without significant toxicity. However, the same effects are not observed in primary rat hepatocytes, indicating cell-specific actions. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 2 mg/mL (7.99 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 85 mg/mL (339.54 mM), Sonication is recommended.
|
| Keywords | ZLN-005 | ZLN005 | ZLN 005 | PPARγ coactivator-1α | PGC-1α | Inhibitor | inhibit | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Valproic Acid | Curcumin | Paeonol | Naringin | Alginic acid | Gefitinib |
| Related Compound Libraries | Glycometabolism Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Autophagy Compound Library | NO PAINS Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |